Business UpdateMay 13, 2026, 11:01 AM
BioRestorative Presents New Preclinical Data on MSC-Derived EVs
AI Summary
BioRestorative Therapies announced the presentation of new preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting. The data highlight distinct functional and proteomic differences in extracellular vesicles (EVs) derived from various mesenchymal stem cell (MSC) sources, including umbilical cord, brown adipose tissue, and bone marrow. These findings provide crucial insights for developing targeted exosome-based formulations for both regenerative medicine and aesthetic applications, supporting the company's BioCosmeceutical platform and broader therapeutic programs.
Key Highlights
- New preclinical data on MSC-derived extracellular vesicles (EVs) presented at ISCT 2026 Annual Meeting.
- Data show distinct functional and proteomic differences across EVs from umbilical cord, brown adipose tissue, and bone marrow.
- Findings enable tailoring exosome-based formulations for specific biological outcomes in regenerative and aesthetic applications.
- Proteomic and gene ontology analyses revealed pathways for proliferation, cell adhesion, immune modulation, and epidermal differentiation.
- Insights support development of differentiated EV-based formulations for BioCosmeceutical platform.
- Potential applications include skin rejuvenation, post-procedural recovery, scar/wound repair, barrier repair, and hair/scalp health.
Price Impact
More from BRTX